**Appendix Table D55. Randomized controlled clinical trials that examined ACE inhibitors of Angiotensin II receptor blockers for migraine prevention in adults**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Active Drug** | **ReferenceSample****Analyzed % Women** | **Definition of MigraineYears of Migraine** | **Eligible Age of Subjects** | **Baseline Migraine Status** |
| Lisinopril | Schrader, 2001136Sample 60Analyzed 55% women 81 | International Headache Society criteriaYears of migraine Not reported | Age 18 to 60 yearsgender, mean (SD): women, 41 (9), men, 43 (5) years | Mean (SD); hours with headache: 65(74), days with headache 9.4(4.0), days with migraine 6.8(3.0) |
| Captopril | Minervini, 1987137Sample 12Analyzed 12% women 58 | Ad Hoc committee on the classification of headacheYears of migraine 7-36 years | Not reported35-64 | Not reported |
| Candesartan | Tonvik, 2003138Sample 60Analyzed 57% women 79 | International Headache Society criteriaYears of migraine Not reported | Age 18 to 65 yearsmean (SD) women: 42(11), men: 48(12) | Mean (SD) of Migraine days 5.7 (2.9)Disability level 9.7 (6.4)Sick leave days 1.00 (2.00) |
| Telmisartan | Diener, 2009139Sample 84Analyzed 84% women 84.5 | International Headache Society criteriaYears of migraine Not reported | 18-65Active group: 39.8 (11.7), placebo: 41.6 (12.9) years | Migraine days active: 6.2 (SD=2.9), placebo: 7.6 (SD=3.7); headache hours active: 58.2 (SD=50.4), placebo: 74.4 (SD=64.2) |